NO323557B1 - Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmate for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene. - Google Patents

Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmate for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene.

Info

Publication number
NO323557B1
NO323557B1 NO980335A NO980335A NO323557B1 NO 323557 B1 NO323557 B1 NO 323557B1 NO 980335 A NO980335 A NO 980335A NO 980335 A NO980335 A NO 980335A NO 323557 B1 NO323557 B1 NO 323557B1
Authority
NO
Norway
Prior art keywords
formulation
reconstituted
stable
formulations
preparation
Prior art date
Application number
NO980335A
Other languages
English (en)
Norwegian (no)
Other versions
NO980335D0 (no
NO980335L (no
NO323557B3 (no
Inventor
Steven J Shire
James Andya
Jeffrey L Cleland
Chung C Hsu
Xanthe M Lam
David E Overcashier
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27056058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323557(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/615,369 external-priority patent/US6267958B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO980335D0 publication Critical patent/NO980335D0/no
Publication of NO980335L publication Critical patent/NO980335L/no
Publication of NO323557B3 publication Critical patent/NO323557B3/no
Publication of NO323557B1 publication Critical patent/NO323557B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO980335A 1995-07-27 1998-01-26 Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmate for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene. NO323557B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US08/615,369 US6267958B1 (en) 1995-07-27 1996-03-14 Protein formulation
PCT/US1996/012251 WO1997004801A1 (en) 1995-07-27 1996-07-23 Stabile isotonic lyophilized protein formulation

Publications (4)

Publication Number Publication Date
NO980335D0 NO980335D0 (no) 1998-01-26
NO980335L NO980335L (no) 1998-03-26
NO323557B3 NO323557B3 (no) 2007-06-11
NO323557B1 true NO323557B1 (no) 2007-06-11

Family

ID=27056058

Family Applications (2)

Application Number Title Priority Date Filing Date
NO980335A NO323557B1 (no) 1995-07-27 1998-01-26 Stabil, rekonstituert formulering og lyofilisert formulering, fremgangsmate for fremstilling av disse, fremstilt artikkel og anvendelse av formuleringene.
NO2007012C NO2007012I1 (no) 1995-07-27 2007-11-05 Trastuzumab eller farmasoytisk akseptable salter derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2007012C NO2007012I1 (no) 1995-07-27 2007-11-05 Trastuzumab eller farmasoytisk akseptable salter derav

Country Status (17)

Country Link
EP (3) EP0845997A1 (de)
JP (7) JPH11510170A (de)
CN (3) CN100360184C (de)
AR (2) AR003969A1 (de)
AU (1) AU716785B2 (de)
BR (1) BR9609743A (de)
CA (2) CA2226575C (de)
DK (2) DK2275119T3 (de)
ES (2) ES2435462T3 (de)
IL (1) IL122910A (de)
MX (1) MX9800684A (de)
NO (2) NO323557B1 (de)
NZ (2) NZ313503A (de)
PT (2) PT2275119E (de)
RU (2) RU2497500C2 (de)
SI (2) SI1516628T1 (de)
WO (1) WO1997004801A1 (de)

Families Citing this family (382)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CA2324467C (en) * 1998-03-26 2002-11-05 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EP2311436A1 (de) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilisierte Protein-Kristalle, diese enthaltende Formulierungen und ihre Herstellungsverfahren
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な６−アミジノ−２−ナフチル４−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
JP2003501479A (ja) 1999-06-12 2003-01-14 ビトプ ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬 剤
EP2977063A1 (de) 1999-06-25 2016-01-27 Genentech, Inc. Methoden zur Behandlung unter Verwendung von Anti-ErbB Antibody-Maytansinoid Konjugaten
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
EP1064934A1 (de) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. Gefriergetrocknete GRF-enthaltende Arzneimittel
EP2110138A1 (de) 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
EP2292263A3 (de) * 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und methoden zur stabilisierung von biologischen Molekülen nach Lyophilisierung
ATE293159T1 (de) 1999-12-14 2005-04-15 Thermo Biostar Inc Stabilisierendes verdünnungsmittel für polypeptide und antigene
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002060484A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
US7825094B2 (en) 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
EP1539239A4 (de) * 2002-07-02 2005-09-14 Smithkline Beecham Corp Neue stabile formulierung
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
WO2004084816A2 (en) * 2003-03-21 2004-10-07 Progenics Pharmaceuticals, Inc. IMPROVED CD4-IgG2 FORMULATIONS
WO2004087213A1 (en) 2003-04-02 2004-10-14 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
WO2005021841A2 (en) 2003-09-03 2005-03-10 Bioforms Methods and apparatus for rapid crystallization of biomolecules
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
US7319032B2 (en) 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
MX2007006822A (es) * 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
CN1313161C (zh) * 2005-01-27 2007-05-02 北京大学临床肿瘤学院 结直肠癌放射免疫导向手术药物及其制备方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
KR20080071192A (ko) * 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969004B1 (de) 2005-12-28 2011-08-10 Novo Nordisk A/S Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
EP2004221A2 (de) 2006-03-23 2008-12-24 Novartis Pharma AG Antitumorzellenantigen-antikörper-therapeutika
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
CN101199483B (zh) * 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
US20080200656A1 (en) * 2007-02-16 2008-08-21 Wyeth Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009028580A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
EP2190478B1 (de) 2007-08-24 2016-03-23 Oncotherapy Science, Inc. Dkk1-onkogen als therapeutisches ziel für krebs und diagnostischer marker
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2244814B1 (de) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Formulierungen von rekombinantem vwf
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EP2085095B1 (de) 2008-01-17 2012-03-07 Philogen S.p.A. Kombination aus einem Anti-EDb-Fibronectin-Antikörper-IL-2-Fusionsprotein und einem B-Zellen bindenden Molekül, B-Zellen-Vorläufern und/oder deren krebserregendem Gegenspieler
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
EP2113253B1 (de) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2349314B1 (de) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
RU2481824C2 (ru) * 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
EP2196476A1 (de) 2008-12-10 2010-06-16 Novartis Ag Antikörperformulierung
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
CN103755808B (zh) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
MX2011009620A (es) 2009-03-31 2011-10-19 Roche Glycart Ag Tratamiento de cancer con un anticuerpo de inmunoglobulina g1 (igg1) humanizado anti receptor de factor de crecimiento epidermico (anti-egfr) e irinotecan.
RU2537142C2 (ru) 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR20120107069A (ko) 2009-08-15 2012-09-28 제넨테크, 인크. 이전에 치료된 유방암의 치료를 위한 항혈관신생 요법
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101653471B1 (ko) 2009-10-01 2016-09-01 에프. 호프만-라 로슈 아게 다단계 최종 여과
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
EP2512450B1 (de) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Transient an polymerträger gekoppelte trockene wachstumshormonzusammensetzungen
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
CN102753975B (zh) 2010-02-19 2015-05-20 卡帝拉药物有限公司 基本上保留免疫原性的被杀死细胞的药物组合物
SG10201401123VA (en) 2010-02-23 2014-08-28 Genentech Inc Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
KR101924653B1 (ko) * 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9458509B2 (en) 2010-07-22 2016-10-04 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
WO2012084829A1 (en) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
BR112014009866A2 (pt) * 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
PL2825558T3 (pl) 2012-03-13 2019-11-29 Hoffmann La Roche Terapia skojarzona w leczeniu raka jajnika
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
EP3446709A1 (de) 2012-08-07 2019-02-27 F. Hoffmann-La Roche AG Kombinationstherapie zur behandlung von glioblastomen
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150216977A1 (en) 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014045081A1 (en) 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014063205A1 (en) 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX367748B (es) * 2012-12-21 2019-09-04 Glenmark Pharmaceuticals Sa Formulación de anticuerpo anti her2.
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
LT3060229T (lt) 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
CN103893135B (zh) * 2014-03-28 2017-01-11 中国医学科学院输血研究所 一种人血浆蛋白c的冻干稳定剂组合物及其用途
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
EP3613433B1 (de) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Antikörper gegen den epidermalen wachstumsfaktor-rezeptor (egfr)
CN106573961B (zh) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
WO2015200027A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Protein formulations
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
JP2017528468A (ja) 2014-09-10 2017-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
EP3221349B1 (de) 2014-11-19 2020-11-04 Axon Neuroscience SE Humanisierte tau-antikörper bei alzheimer-krankheit
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3250927B1 (de) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Genexpressionsmarker und behandlung von multipler sklerose
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
EP3287139B1 (de) 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nervenwachstumsfaktorzusammensetzung und injektionspulver
US11077193B2 (en) 2015-04-21 2021-08-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
EP4710947A3 (de) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Cnp-agonisten mit kontrollierter freisetzung mit reduzierten nebenwirkungen
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
CN108463215A (zh) * 2016-01-12 2018-08-28 尹特荣生物科技株式会社 抗菌蛋白的冷冻干燥制剂
AU2017208114B2 (en) 2016-01-12 2023-04-13 Intron Biotechnology, Inc. An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
US11297828B2 (en) 2016-03-14 2022-04-12 The Regents Of The University Of Michigan Surface tension mediated lyo-processing technique for preservation of biologics
BR112018073133A2 (pt) 2016-05-10 2019-04-30 Genentech Inc métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
DK3463308T4 (da) 2016-06-01 2026-02-09 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CN110022855B (zh) * 2016-10-07 2024-07-16 瑞泽恩制药公司 室温稳定的冻干蛋白质
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CA3047170A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
CA3047298C (en) 2016-12-15 2023-12-12 Talengen International Limited Drug for preventing and treating osteoporosis and use thereof
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
EP3615574B1 (de) 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Spezifisch glypican 3 erkennende konstrukte und deren verwendung
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
RU2766590C2 (ru) 2017-05-16 2022-03-15 Цзянсу Хэнжуй Медисин Ко., Лтд. Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
CA3109871A1 (en) 2017-08-22 2019-02-28 Monash University Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage)
IL274071B2 (en) 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
US11642397B2 (en) 2017-12-15 2023-05-09 Talengen International Limited Method and drug for preventing or treating osteoarthritis
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019244481A1 (en) 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12259395B2 (en) 2018-08-17 2025-03-25 Ab Studio Inc. Catabodies and methods of use thereof
EP3852784A1 (de) 2018-09-20 2021-07-28 Mandalmed, Inc. Verfahren und zusammensetzungen zur vorbeugung, behandlung und umkehrung von leberfibrose
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
WO2020089743A1 (en) * 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
JP7627216B2 (ja) 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対する抗体およびそれを使用する方法
CN116003597A (zh) 2018-11-27 2023-04-25 舒泰神（北京）生物制药股份有限公司 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN111375057B (zh) * 2018-12-28 2024-06-21 上海复宏汉霖生物技术股份有限公司 一种包含抗Her2单克隆抗体的药物配制剂
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
EP3923906A1 (de) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Trockene pharmazeutische formulierungen von cnp-konjugaten
JP2022525275A (ja) 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
EP3997121A4 (de) 2019-07-09 2024-03-27 Beijing SoloBio Genetechnology Company Ltd. Antikörper, die spezifisch pseudomonas pcrv erkennen, und deren verwendungen
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3808777A1 (de) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Stabile flüssige antikörperformulierungen
US20230066726A1 (en) 2020-01-17 2023-03-02 Talengen International Limited Method for treatment of nerve injury and related disease
TWI787732B (zh) 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
JP7715722B2 (ja) 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
CN115666625A (zh) 2020-03-24 2023-01-31 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
KR20220158036A (ko) 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
US20230173039A1 (en) 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
JP7624238B2 (ja) 2020-03-24 2025-01-30 タレンゲン インターナショナル リミテッド ハンチントン病を治療する方法及び薬剤
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
US20240092903A1 (en) * 2020-06-12 2024-03-21 Ichnos Sciences SA Antibody formulation diluent
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
EP4180454A4 (de) 2020-07-10 2024-10-02 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige-manipulierter antikörper und anwendung davon
IL300121A (en) 2020-07-29 2023-03-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
KR20230048422A (ko) 2020-08-14 2023-04-11 에프. 호프만-라 로슈 아게 오크렐리주맙으로 다발성 경화증을 치료하는 방법
CN114246944A (zh) * 2020-09-24 2022-03-29 盛禾(中国)生物制药有限公司 一种双特异性抗体的药物组合物及其用途
PH12023550779A1 (en) 2020-09-28 2023-11-20 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof
AU2021381982A1 (en) * 2020-11-20 2023-06-08 Genentech, Inc. Reusable cartridges for detecting analytes in solution
CN112684177B (zh) * 2020-12-17 2024-05-28 北京维德维康生物技术有限公司 一种乳品多因子快速检测试剂盒及其检测方法
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
US20240269279A1 (en) * 2021-06-14 2024-08-15 Novartis Ag PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY
EP4355785A1 (de) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3-konstrukte und verwendungen davon
CN118103397A (zh) 2021-07-08 2024-05-28 舒泰神(加州)生物科技有限公司 特异性识别tnfr2的抗体及其用途
JP7833531B2 (ja) 2021-07-14 2026-03-19 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
EP4445911A4 (de) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd Bispezifischer antikörper mit spezifischer bindung an klebsiella pneumoniae-o2- und o1-antigene sowie zusammensetzung
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用
EP4524158A4 (de) 2022-05-09 2025-12-17 Staidson Beijing Biopharmaceuticals Co Ltd Antikörper mit spezifischer gdf15-erkennung und verwendung davon
EP4558226A1 (de) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antikörper, die spezifisch b- und t-lymphozyten-dämpfungsglied (btla) erkennen, und verwendungen davon
KR20250049554A (ko) 2022-08-19 2025-04-11 이바이브 바이오테크놀로지 (상하이) 엘티디 G-csf를 포함하는 제형 및 이의 용도
US20260078185A1 (en) 2022-09-07 2026-03-19 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
CN120693395A (zh) 2022-10-20 2025-09-23 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
CN115746082B (zh) * 2022-12-02 2024-12-10 大连工业大学 一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用
EP4725501A1 (de) 2023-06-09 2026-04-15 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Spezifisch an masp3 bindende antikörper und spezifisch an masp3 und masp2 bindender multispezifischer antikörper
EP4729546A1 (de) 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antikörper zur spezifischen erkennung von faktor xiia und verwendung davon
IL325726A (en) 2023-07-11 2026-03-01 Genentech Inc Compositions and methods for treating multiple sclerosis
WO2025167631A1 (zh) 2024-02-05 2025-08-14 北京三诺佳邑生物技术有限责任公司 特异性结合HBV pre-S1抗原、PD-L1抗原和CD3抗原的多特异性抗体及其应用
WO2026050244A1 (en) 2024-08-26 2026-03-05 Angitia Incorporated Limited Methods of treating or preventing osteoporosis and low bone mass

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896028A (ja) * 1981-11-30 1983-06-07 Takeda Chem Ind Ltd ヒトＩｇＥの製造法
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0827283B2 (ja) * 1986-03-10 1996-03-21 財団法人化学及血清療法研究所 免疫凝集反応用組成物
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPS62289523A (ja) * 1986-06-09 1987-12-16 Green Cross Corp:The 静脈投与用免疫グロブリンの加熱処理方法
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68920693T2 (de) * 1988-03-30 1995-05-24 Toray Industries Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
JPH01268645A (ja) * 1988-04-18 1989-10-26 Teijin Ltd シュワルツマン反応抑制剤
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
CN1047342A (zh) * 1989-05-13 1990-11-28 杭州市中心血站 因子viii的生产及其病毒灭活方法
EP0478715B1 (de) * 1989-06-23 1996-04-03 The Liposome Company, Inc. Zielliposomen und verfahren zur kupplung von liposomen-proteinen
EP0739904A1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische Reagenzien für die AIDS-Therapie
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (de) * 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
CA2120701A1 (en) * 1991-10-11 1993-04-15 Sharon M. Devereaux Unit-of-use reagent composition for specific binding assays
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
FR2708467B1 (fr) * 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
JP4142095B2 (ja) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
EP2275119A1 (de) 2011-01-19
RU2013141049A (ru) 2015-03-20
NO2007012I1 (no) 2007-11-29
SI1516628T1 (sl) 2013-10-30
JPH11510170A (ja) 1999-09-07
EP1516628B1 (de) 2013-08-21
JP2007238628A (ja) 2007-09-20
NO980335D0 (no) 1998-01-26
CN1151842C (zh) 2004-06-02
ES2435462T3 (es) 2013-12-19
JP2007217430A (ja) 2007-08-30
DK2275119T3 (da) 2013-11-11
AR003969A1 (es) 1998-09-30
CA2226575A1 (en) 1997-02-13
CN102416176A (zh) 2012-04-18
JP2016033156A (ja) 2016-03-10
RU2497500C2 (ru) 2013-11-10
NZ313503A (en) 2000-01-28
CN1539505A (zh) 2004-10-27
IL122910A0 (en) 1998-08-16
AR074517A2 (es) 2011-01-26
IL122910A (en) 2002-05-23
PT1516628E (pt) 2013-09-24
CA2226575C (en) 2011-10-18
NO980335L (no) 1998-03-26
NZ500539A (en) 2001-11-30
PT2275119E (pt) 2013-11-21
HK1152876A1 (en) 2012-03-16
HK1117075A1 (en) 2009-01-09
CA2745743A1 (en) 1997-02-13
JP2011256205A (ja) 2011-12-22
SI2275119T1 (sl) 2013-12-31
WO1997004801A1 (en) 1997-02-13
NO323557B3 (no) 2007-06-11
EP0845997A1 (de) 1998-06-10
AU6599296A (en) 1997-02-26
JP2017039778A (ja) 2017-02-23
CN100360184C (zh) 2008-01-09
EP2275119B1 (de) 2013-09-25
CN1191490A (zh) 1998-08-26
EP1516628A1 (de) 2005-03-23
ES2434840T3 (es) 2013-12-17
JP5043507B2 (ja) 2012-10-10
AU716785B2 (en) 2000-03-09
DK1516628T3 (da) 2013-09-08
JP5043506B2 (ja) 2012-10-10
JP2011256206A (ja) 2011-12-22
MX9800684A (es) 1998-04-30
BR9609743A (pt) 1999-03-02

Similar Documents

Publication Publication Date Title
MX9800684A (es) Formulacion de proteinas liofilizadas isotonicas estables.
Beachey et al. Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen
FI932561A7 (fi) Proteiinit, joilla on muuttuneet epitoopit ja menetelmiä niiden valmistamiseksi
CZ108195A3 (en) Stable lyophilized protein-containing preparation and a dosing kit thereof
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
Cryz Jr et al. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans
JP2001521544A (ja) 免疫グロブリン含有組成物
ATE219683T1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
US4079126A (en) Method of preparing a component consisting of sugar, lipid and protein derived from Pseudomonas aeruginosa which possess anti-tumor and interferon inducing properties
AU3075995A (en) Process for modifying the stability of antibodies
CS196267B2 (en) Method of producing water-soluble compounds having low-molecular weight,containing diamino pimelic acid
Brubaker et al. Proteolysis of V antigen from Yersinia pestis
EP1338607A3 (de) Mit der Familie der Hämolysin-Toxine verwandte Antigene Eisen-unterdrückende Proteine der N. Meningitis
Lopez-Merino et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances
US4033819A (en) Derivatives of diphtheria toxin, process for preparing them and agents containing them
Possani et al. Detoxification with glutaraldehyde of purified scorpion (Centruroides noxius Hoffmann) venom
BR9709993A (pt) Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
Migliore-Samour et al. Hydrosoluble immunopotentiating substances extracted from Corynebacterium parvum
NO920163L (no) Hydrolysert vegetabilsk protein og fremstilling av et slikt
Cryz Jr et al. Toxoids of Pseudomonas aeruginosa toxin A: production by chemical and genetic means
SG143058A1 (en) Method and composition for altering a t cell mediated pathology
Tatu et al. Role of a disulfide cross-link in the conformational stability of a thermostable xylanase
Sugiyama et al. Immunological Reactivity of Trypsinized Clostridium botulinum Type E Toxin.
Vosti et al. Extraction of streptococcal type 12 M protein by cyanogen bromide
JPS63225320A (ja) 抗体を含有する安定水性組成物

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Spc suppl protection certif: SPC/NO 2007 012

Filing date: 20071105

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2007012

Effective date: 20161129